| 50.52 -0.81 (-1.58%) | 02-12 19:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 63.18 | 1-year : | 73.8 |
| Resists | First : | 54.09 | Second : | 63.18 |
| Pivot price | 45.32  |
|||
| Supports | First : | 35.41 |
Second : | 23.86 |
| MAs | MA(5) : | 50.08 |
MA(20) : | 42.17 |
| MA(100) : | 21.76 |
MA(250) : | 10.79 |
|
| MACD | MACD : | 6.1 |
Signal : | 5.7 |
| %K %D | K(14,3) : | 87.6 |
D(3) : | 88 |
| RSI | RSI(14): 68.8 |
|||
| 52-week | High : | 54.09 | Low : | 1.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MNPR ] has closed below upper band by 23.8%. Bollinger Bands are 61.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 51.81 - 52.1 | 52.1 - 52.33 |
| Low: | 48.38 - 48.73 | 48.73 - 49.01 |
| Close: | 49.99 - 50.53 | 50.53 - 50.97 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Wed, 12 Feb 2025
Brookline Capital Management Weighs in on MNPR Q1 Earnings - MarketBeat
Thu, 06 Feb 2025
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Mon, 03 Feb 2025
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - Yahoo Finance
Mon, 23 Dec 2024
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways (MNPR) - Seeking Alpha
Fri, 06 Dec 2024
Monopar Therapeutics Achieves Milestone in Cancer Treatment - TipRanks
Mon, 28 Oct 2024
Monopar Therapeutics announces public stock offering - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 42.9 (%) |
| Held by Institutions | 24.4 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 652 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53.5 % |
| Return on Equity (ttm) | -102.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -25.52 |
| PEG Ratio | 0 |
| Price to Book value | 26.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -45.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|